Disrupting cancer through SurVaxM immunotherapy

At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients

News and Events

Here is the place that we keep you updated about our latest News and Publications

George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16, 2019)

October 7, 2019

MimiVax to present results of SurVaxM in glioblastoma at ASCO 2019 Meeting

Updated median progression free survival (mPFS) is 15.5 months from diagnosis. Median overall survival (OS) is at 30.5 months from diagnosis. SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in glioblastoma with minimal toxicity.

June 05, 2019

Mimivax looks for game-changer in GBM as Survaxm shows signal at interim look

In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint. 

May 21, 2018

MimiVax

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates

PartnerING

MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.

Pipeline

We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.

Clinical Trials

SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET). 

“The Jacobs family has a deep passion for the discovery of new drugs and medical devices that will help ease the suffering and offer improved treatments for patients diagnosed with chronic and terminal diseases.”

Jerry Jacobs Jr
Board of Directors at Mimivax
"Immunotherapy offers great hope for patients with cancer. Advances in this arena will undoubtedly lead to significant improvements in survival, including for those patients with difficult to treat malignancies. Many experts in the field believe that glioblastoma is potentially susceptible to immunotherapy. Here at MimiVax, we have devoted our lives and careers to uncovering the clues that will help make that belief a reality."
Robert A. Fenstermaker, MD
Leadership Team at Mimivax

Our History

OUR MISSION

To disrupt cancer with innovative immunotherapies

SurVaxM is currently being evaluated in: a Phase II clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).

0
Clinical trials
0
Disease Indications
50
Patient Participants
50
Doses Delivered

Disrupt cancer with the development of highly innovative immunotherapies

Newsroom

SurVaxM

Partner with us

MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.

MimiVax is a team of experienced scientists, leading clinicians and industry leaders.

We are committed to pursuing the most efficient and comprehensive path to deliver upon the promise of SurVaxM to improve the lives of those battling cancer.

Contact us